Table 5.

Univariable analysis of influence of waiting time on disease-free survival and overall survival in patients treated with neoadjuvant therapy followed by esophagectomy for esophageal cancer

	Disease-free survival			Overall survival
	HR	95 % CI	p value	HR	95 % CI	p value
Univariable analysis
Additional week waiting time	0.96	0.88–1.05	0.362	1.00	0.91–1.08	0.910
Age at diagnosis	1.01	0.91–1.13	0.805	1.01	0.98–1.03	0.503
Gender
Female	Reference	–	–	Reference	–	–
Male	1.28	0.77–2.13	0.342	1.01	0.62–1.65	0.962
ASA classification
1	Reference	–	–	Reference	–	–
2	0.84	0.52–1.33	0.452			0.389
>3	1.33	0.72–2.47	0.366	0.81	–	0.480
Tumor location
Upper esophagus	Reference	–	–	Reference	–	–
Middle esophagus	0.59	0.12–3.06	0.534	0.61	0.13–2.83	0.524
Distal esophagus	0.87	0.19–3.95	0.853	0.74	0.18–3.05	0.677
Gastroesophageal junction	0.70	0.15–3.24	0.647	0.53	0.13–2.23	0.389
Neoadjuvant therapy
Chemotherapy	Reference	–	–	Reference	–	–
Chemoradiotherapy	0.90	0.60–1.34	0.594	0.96	0.63–1.46	0.849
Surgical approach
Transthoracic	Reference	–	–	Reference	–	–
Transhiatal	0.75	0.44–1.26	0.272	0.72	0.43–1.22	0.226
Histological type
Adenocarcinoma	Reference	–	–	Reference	–	–
Squamous cell carcinoma	0.87	0.49–1.53	0.621	1.45	0.85–2.45	0.172
pT stage
T0	Reference	–	–	Reference	–	–
T1-2	1.55	0.69–3.47	0.288	0.95	0.45–2.02	0.895
T3-4a	3.94	1.89–8.25	<0.001	2.54	1.31–4.94	0.006
pN stage
N0	Reference	–	–	Reference	–	–
N1	1.83	1.11–3.03	0.019	2.07	1.25–3.43	0.005
N2-3	4.42	2.77–7.03	<0.001	4.15	2.57–6.69	<0.001
Radicality
R0	Reference	–	–	Reference	–	–
R1	4.41	2.46–7.91	<0.001	4.40	2.46–7.87	<0.001
Referral
By general practitioner	Reference	–	–	Reference	–	–
By another hospital	0.94	0.52–1.72	0.847	0.93	0.53–1.78	0.928
Additional year date diagnosis	1.01	0.91–1.13	0.805	1.07	0.95–1.21	0.250

Analysis was performed using Cox regression model

ASA American Society of Anesthesiologists, HR hazard ratio, CI confidence interval